Skip to main content
. 2024 Jan 2;34(1):58–75. doi: 10.1038/s41422-023-00909-w

Fig. 7. ZNF689 expression positively correlates with a favorable prognosis and immunotherapy response in TNBC.

Fig. 7

a Analysis of the correlation of ZNF689 expression with LINE-1 ORF1p, CD8, and histologic ITH in TNBC tissues (n = 283). b Kaplan–Meier analysis of OS, RFS, and DMFS in TNBC patients from FUSCC grouped according to the expression of ZNF689. c Multiplex IF staining in one representative responder and one non-responder treated with anti-PD-1-based immunotherapy. Scale bars, 50 µm. d Quantification of ZNF689 expression in responders and non-responders in four trials. e Analysis of ZNF689 mRNA levels in all responder versus non-responder patients in the melanoma cohort (GSE91061) and urothelial cancer cohort (GSE176307). f Illustration of the proposed working model. P values were determined using Pearson’s χ2 test (a), log-rank test (b), two-tailed unpaired Student’s t-test (d), and one-tailed Student’s t-test (e). *P < 0.05, **P < 0.01, ***P < 0.001.